The 4 most recent market catalysts affecting $JANX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 75
Janux Therapeutics shares are trading higher after Wolfe Research upgraded the stock from Peer Perform to Outperform rating and announced a $23 price target.
This headline indicates a strong positive catalyst for Janux Therapeutics. Analyst upgrades, especially from 'Peer Perform' to 'Outperform' with a specific price target, often act …
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 65
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target
Wolfe Research analyst Kalpit Patel upgraded Janux Therapeutics (JANX) from 'Peer Perform' to 'Outperform' and announced a new price target of $23. This upgrade indicates a more po…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55
Guggenheim analyst Brad Canino maintained a 'Buy' rating on Janux Therapeutics but adjusted the price target downwards from $58 to $55. This action signals that while the analyst s…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 92
Janux Therapeutics Q2 EPS $(0.35) Beats $(0.38) Estimate, Sales $10.267M Miss $16.493M Estimate
Janux Therapeutics' Q2 earnings report presents a mixed picture. While the company successfully narrowed its losses per share, beating analyst expectations, the substantial miss on…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.